

**Anti-DLL3 Reference Antibody (rovalpituzumab-MMAE)
Recombinant Antibody
Catalog # APR10109****Specification**

Anti-DLL3 Reference Antibody (rovalpituzumab-MMAE) - Product Information


Application	FC, Kinetics, Animal Model
Primary Accession	Q9NYJ7
Reactivity	Rat, Human, Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	145 KDa

Anti-DLL3 Reference Antibody (rovalpituzumab-MMAE) - Additional Information**Target/Specificity**
DLL3**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-DLL3 Reference Antibody (rovalpituzumab-MMAE) - Protein Information****Name** DLL3**Function**
Inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm (By similarity).**Cellular Location**
Membrane; Single-pass type I membrane protein**Anti-DLL3 Reference Antibody (rovalpituzumab-MMAE) - Protocols**


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-DLL3 Reference Antibody (rovalpituzumab-MMAE) - Images



Anti-DLL3 Reference Antibody (rovalpituzumab-MMAE) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-DLL3 Reference Antibody (rovalpituzumab-MMAE) is more than 95%, determined by SEC-HPLC.